US 11,891,387 B2
Monoacylglycerol lipase modulators
Michael K. Ameriks, San Diego, CA (US); Brian Ngo Laforteza, San Diego, CA (US); Suchitra Ravula, San Diego, CA (US); Jamie M. Schiffer, San Diego, CA (US); and Brice M. Stenne, La Jolla, CA (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Filed by Janssen Pharmaceutica NV, Beerse (BE)
Filed on Mar. 25, 2021, as Appl. No. 17/212,377.
Claims priority of provisional application 63/000,329, filed on Mar. 26, 2020.
Prior Publication US 2022/0372030 A1, Nov. 24, 2022
Int. Cl. C07D 471/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 519/00 (2013.01)] 19 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
wherein
R1a is C1-4alkyl;
R1b is H;
or R1a and R1b taken together form —CH2CH2— or —CH2CH2CH2—;
R2 is selected from:
(a) phenyl or pyridyl, each optionally substituted with one or two substituents selected from halo, C1-4alkyl, C1-4haloalkyl, OC1-4alkyl, OC1-4haloalkyl, N-linked monocyclic or bicyclic heterocycloalkyl, monocyclic heteroaryl, and C3-6cycloalkyl, or two adjacent ring substituents taken together with the carbons to which they are attached form a monocyclic cycloalkyl or hetercycloalkyl ring; and
(b) bicyclic heteroaryl optionally substituted with one or two substituents selected from halo, C1-4alkyl, C1-4haloalkyl, OC1-4alkyl, OC1-4haloalkyl, N-linked monocyclic or bicyclic heterocycloalkyl, monocyclic heteroaryl, and C3-6cycloalkyl; and
R3 is 1H—C1-4alkyl-pyrazolyl, 1H—C1-4haloalkyl-pyrazolyl, 1H-pyridyl-pyrazolyl, 1H—(C3-6cycloalkyl)-pyrazolyl, or 1H—(C3-6cycloalkyl-methyl)-pyrazolyl, each pyrazolyl optionally substituted with halo, C1-4alkyl, C1-4haloalkyl, OC1-4alkyl, or OC1-4haloalkyl;
provided that when R2 is phenyl or pyridyl, each optionally substituted with halo, C1-4alkyl, or C1-4haloalkyl, then (a) R1a and R1b are taken together form —CH2CH2— or —CH2CH2CH2—;
or (b) R3 is not 1H—C1-4alkyl-pyrazol-5-yl

OG Complex Work Unit Chemistry
 or 1H—C1-4haloalkyl-pyrazol-5-yl

OG Complex Work Unit Chemistry
 or a pharmaceutically acceptable salt, isotope, N-oxide, solvate, or stereoisomer thereof.